{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:05:11Z","timestamp":1792209911807,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.tcm.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T15:18:13Z","timestamp":1499959093000},"page":"10-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":300,"title":["Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment"],"prefix":"10.1016","volume":"28","author":[{"given":"Omar K.","family":"Siddiqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2017.07.004_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril","volume":"130","author":"Sipe","year":"2000","journal-title":"J Struct Biol"},{"key":"10.1016\/j.tcm.2017.07.004_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tcm.2017.07.004_bib4","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0006-291X(81)90764-6","article-title":"The prealbumin nature of the amyloid protein in familial amyloid polyneuropathy (FAP)-swedish variety","volume":"99","author":"Skinner","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.tcm.2017.07.004_bib5","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","article-title":"Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy","volume":"75","author":"Costa","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tcm.2017.07.004_bib6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/msj.21352","article-title":"Amyloid neuropathies","volume":"79","author":"Shin","year":"2012","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib8","first-page":"426","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation.","volume":"75","author":"Stables","year":"1996","journal-title":"Heart (Br Card Soc)"},{"key":"10.1016\/j.tcm.2017.07.004_bib9","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib10","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506129.2011.571319","article-title":"Myocardial infarction with \u201cclean coronaries\u201d caused by amyloid light-chain AL amyloidosis: a case report and literature review","volume":"18","author":"Tsai","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2017.07.004_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.tcm.2017.07.004_bib13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2017.07.004_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/emmm.201404190","article-title":"Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity","volume":"6","author":"Guan","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib15","doi-asserted-by":"crossref","first-page":"H2305","DOI":"10.1152\/ajpheart.00503.2011","article-title":"Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins","volume":"301","author":"Migrino","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.tcm.2017.07.004_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2559.2007.02658.x","article-title":"Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients","volume":"50","author":"Hasserjian","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.tcm.2017.07.004_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","article-title":"High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement","volume":"119","author":"Madan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tcm.2017.07.004_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","author":"Gonzalez-Lopez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.07.004_bib21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib22","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.07.004_bib23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2004.10.028","article-title":"Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement","volume":"95","author":"Murtagh","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1536\/ihj.15-005","article-title":"Contribution of electrocardiogram in the differentiation of cardiac amyloidosis and nonobstructive hypertrophic cardiomyopathy","volume":"56","author":"Huang","year":"2015","journal-title":"Int Heart J"},{"key":"10.1016\/j.tcm.2017.07.004_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1540-8175.1991.tb01395.x","article-title":"Two-dimensional echocardiography in myocardial amyloidosis","volume":"8","author":"Picano","year":"1991","journal-title":"Echocardiography (Mount Kisco, NY)"},{"key":"10.1016\/j.tcm.2017.07.004_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.tcm.2017.07.004_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0167-5273(92)90115-J","article-title":"Cardiac tamponade as presentation of systemic amyloidosis","volume":"36","author":"Navarro","year":"1992","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13506121003619310","article-title":"How to diagnose cardiac amyloidosis early: impact of ECG, tissue Doppler echocardiography, and myocardial biopsy","volume":"17","author":"Piper","year":"2010","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2017.07.004_bib31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib32","first-page":"748","article-title":"Prognostic implication of relative regional strain ratio in cardiac amyloidosis","volume":"102","author":"Senapati","year":"2016","journal-title":"Heart (Br Card Soc)"},{"key":"10.1016\/j.tcm.2017.07.004_bib33","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jcmg.2015.11.013","article-title":"The relation of ejection fraction and global longitudinal strain in amyloidosis: implications for differential diagnosis","volume":"9","author":"Pagourelias","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","article-title":"Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers","volume":"60","author":"Buss","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jcmg.2016.04.008","article-title":"Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system","volume":"10","author":"Barros-Gomes","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib36","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","author":"Salinaro","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2008.09.105","article-title":"Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis","volume":"103","author":"Ruberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib38","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcmg.2009.08.008","article-title":"Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis","volume":"2","author":"Austin","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ehjci\/jew101","article-title":"Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis","volume":"17","author":"Bhatti","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","article-title":"LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis","volume":"9","author":"Boynton","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib43","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcmg.2012.04.006","article-title":"Quantification of extracellular matrix expansion by CMR in infiltrative heart disease","volume":"5","author":"Mongeon","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib45","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib46","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m Pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib47","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"11C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2017.07.004_bib49","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2017.07.004_bib50","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archinte.1988.00380040169024","article-title":"Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain)","volume":"148","author":"Gertz","year":"1988","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.tcm.2017.07.004_bib51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/archinte.1983.00350080055015","article-title":"Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis","volume":"143","author":"Libbey","year":"1983","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx210","article-title":"Challenging the myths of cardiac amyloidosis","author":"Siddiqi","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2017.07.004_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2016-06-721878","article-title":"The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tcm.2017.07.004_bib54","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tcm.2017.07.004_bib55","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tcm.2017.07.004_bib56","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib57","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2017.07.004_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2017.07.004_bib59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/13506129.2013.845745","article-title":"Genotype, echocardiography, and survival in familial transthyretin amyloidosis","volume":"20","author":"Arruda-Olson","year":"2013","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2017.07.004_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.tcm.2017.07.004_bib61","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib62","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.tcm.2017.07.004_bib63","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib64","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib66","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.tcm.2017.07.004_bib67","first-page":"263","article-title":"Liver transplantation for hereditary transthyretin amyloidosis. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation","volume":"6","author":"Suhr","year":"2000","journal-title":"Society"},{"key":"10.1016\/j.tcm.2017.07.004_bib68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.tcm.2017.07.004_bib69","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","article-title":"Outcome of heart transplantation in patients with amyloid cardiomyopathy","volume":"24","author":"Kpodonu","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.tcm.2017.07.004_bib70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Castano","year":"2012","journal-title":"Congest Heart Fail (Greenwich, Conn)."},{"key":"10.1016\/j.tcm.2017.07.004_bib71","first-page":"2658","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"J Am Med JAssoc"},{"key":"10.1016\/j.tcm.2017.07.004_bib72","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.tcm.2017.07.004_bib73","doi-asserted-by":"crossref","first-page":"97ra81","DOI":"10.1126\/scitranslmed.3002473","article-title":"Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity","volume":"3","author":"Alhamadsheh","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.tcm.2017.07.004_bib75","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib76","series-title":"Clinical development of an antisense therapy for the treatment of hereditary transthyretin amyloidosis","author":"Ackermann","year":"2012"},{"key":"10.1016\/j.tcm.2017.07.004_bib77","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.tcm.2017.07.004_bib78","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","article-title":"Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy","volume":"1782","author":"Macedo","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.tcm.2017.07.004_bib79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib80","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.febslet.2011.06.030","article-title":"Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation","volume":"585","author":"Ferreira","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.tcm.2017.07.004_bib81","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tcm.2017.07.004_bib82","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure","volume":"67","author":"Sperry","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2017.07.004_bib83","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tcm.2017.07.004_bib84","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib85","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Supp1.","key":"10.1016\/j.tcm.2017.07.004_bib86","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2017.07.004_bib87","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2017.07.004_bib88","first-page":"202","article-title":"Long term results of heart transplantation in patients with amyloid heart disease.","volume":"85","author":"Dubrey","year":"2001","journal-title":"Heart (Br Card Soc)"},{"key":"10.1016\/j.tcm.2017.07.004_bib89","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/TP.0b013e3181f10edb","article-title":"Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure","volume":"90","author":"Dey","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.tcm.2017.07.004_bib90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","article-title":"Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis","volume":"33","author":"Gray Gilstrap","year":"2014","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.tcm.2017.07.004_bib91","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transpl"},{"key":"10.1016\/j.tcm.2017.07.004_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transpl"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173817301081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173817301081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:58:23Z","timestamp":1760936303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173817301081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1050173817301081"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2017.07.004","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}